ClinicalTrials.gg
RecruitingNCT05197309Updated Feb 27, 2026

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

An interventional study of Metabolic Diet in Anorexia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Planned enrollment
109th of 143
20 · median 40
Started
2022
with 15 others
No phase
94 of 174
24 open now
Primary completion
2026-12
later than 11 of 44 live
Registered
121st of 174
by date
Lead sponsor
5 of 174
Icahn School of Medicine at Mount Sinai

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 109th largest by planned enrollment of the 143 interventional ones that give a count, is one of 16 that started in 2022, is one of 94 with no phase, reaches primary completion later than 11 of the 44 other live ones, and was the 121st registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

This is an interventional study that will test the safety, tolerability, and efficacy of the Metabolic Diet, which was designed as a treatment for women with anorexia nervosa to remain weight-stable after they have been restored from low weight. Participants will be adult women with anorexia nervosa who have been recently restored to normal weight and adult women with no history of eating disorders. After enrollment, participants will start meeting weekly with a registered dietitian to implement the Metabolic Diet in their daily lives, and will receive medical monitoring for adherence, side effects, changes in metabolic or psychological parameters, and weight stability.

Read the detailed description

The study plan to enroll a total of 20 subjects from the broader New York City area into an 8-week eating behavioral program. Of the 20, 10 will be weight-restored patients with anorexia nervosa (WR-AN) and the other 10 will be age-, sex-, and body mass index (i.e. weight) matched healthy controls (HC).

The primary study intervention is an eating behavioral program called, Metabolic Diet, which is aimed to change the proportion of macronutrients in their meals to incorporate higher fat content and lower the carbohydrate content to limit fluctuations in circulating blood glucose levels throughout the day, which may contribute to a relapse in anorexia nervosa. Participants will be guided to start the Metabolic Diet following the first 2 individual study visits, and the duration of the primary intervention is for 8 weeks. As part of the intervention, each subject will keep a food log and measure the urinary ketones at home, which they will discuss with the study providers during weekly visits. Each subject will meet individually with the Study Dietician and with the Study Physician on a weekly basis. At these visits, food logs and ketone logs will be reviewed so that subjects' adherence to the Metabolic Diet can be assessed and facilitated.

Surveys and lab work are completed during screening, week 4 and week 8.

03

Conditions studied

  • Anorexia Nervosa

Keywords

  • anorexia nervosa
  • metabolic diet
  • weight-restored
  • eating disorders
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Age at least 18 and not over 40
  • at or above 18.5 kg/m2
  • Speaks English
  • Medically stable, as cleared by a licensed physician, with vital signs and initial blood draws
  • History of diagnosis of Anorexia Nervosa (WR-AN only)
  • Weight-restored from underweight BMI (under 18.5 kg/m2) within the past 6 months (WR-AN only)

Exclusion criteria

Exclusion Criteria:

  • Current/lifetime diagnosis of psychotic disorders, bipolar disorders
  • Active DSM-5 substance use disorders
  • On medications that could affect metabolism

    *Subjects are to be free of any medications that could affect metabolism, as discussed with study physician, for 2 weeks prior to primary study visit for glucose function testing.

  • History of suicide attempt within previous 6 months or acute suicide risk
  • Significant current medical illness or metabolic conditions, including diabetes mellitus and pregnancy
  • Current/lifetime diagnosis of DSM-5 eating disorders (HC only)
  • Active DSM-5 depressive disorders (HC only)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Women with anorexia nervosa

    adult women with anorexia nervosa who have been recently restored to normal weight

    Dietary Supplement: Metabolic Diet

  • Active comparator
    Women with no history of eating disorders

    adult women with no history of eating disorders

    Dietary Supplement: Metabolic Diet

Interventions

  • Dietary supplementMetabolic Diet

    Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Safety of intervention will be measured by # of adverse events reported over 10 weeks. Adverse events will be documented during each of the 8 weekly clinician visits.

    Time frame: 10 weeks

  2. Percent completion of food

    Tolerability of intervention will be measured using percent completion of food over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.

    Time frame: 10 weeks

  3. Percent completion of ketone logs

    Tolerability of intervention will be measured using percent completion of ketone logs over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.

    Time frame: Baseline to 10 weeks

Secondary outcomes

  1. Change in Weight

    Weight will be calculated using the baseline weight and weight at the 10 week assessment. Weight will be during each of the 8 weekly clinician visits.

    Time frame: Baseline and 10 weeks

  2. Change in Eating Disorder Examination Questionnaire (EDE-Q)

    Changes in Dietary Behavior using the Eating Disorder Examination Questionnaire (EDE-Q). Dietary restraint, eating, shape, and weight concerns are measured with the EDE-Q at multiple time points. Subscales for dietary restraint, eating, shape, and weight (subscales range from 0-6) concerns are summed and then divided by the total number of subscales (4) to create a global score (total scale 0 to 6). Higher scores on the global scale and subscales indicate more problematic eating behaviors and attitudes. Changes in the EDE-Q global score will be calculated using the baseline and 10 week assessments.

    Time frame: Baseline and 10 weeks

  3. Changes in Anxiety using the Beck Anxiety Inventory (BAI)

    The intensity and physical symptoms of anxiety are measures with the BAI at baseline and 10 weeks. Scores may range from 0 to 63. Higher scores indicate more intense anxiety symptoms. Changes in the BAI score will be calculated using the baselines and 10 week assessments.

    Time frame: Baseline and 10 weeks

  4. Changes in Mood using the Quick Inventory of Depressive Symptomatology (QIDS)

    Depression is measured with the QIDS at baseline and 10 weeks. Scores may range from 0 to 27. Higher scores indicate a higher severity of depression. Changes in the QIDS score will be calculated using the baselines and 10 week assessments.

    Time frame: Baseline and 10 weeks

  5. Changes in Clinical Impairments using the Clinical Impairment Assessment (CIA)

    Psychosocial functioning from eating disorders is measured using the CIA. Scores range from 0 to 48. Higher scores indicate more impairment associated with an eating disorder.

    Time frame: Baseline and 10 weeks

  6. Changes in Quality of Life using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) from Baseline to 10 Weeks

    Quality of life is measured using the QLESQ. Scores range from 14 to 70 and higher scores indicate a quality.

    Time frame: Baseline and 10 weeks

  7. Changes in Carbon Dioxide (CO2)

    The laboratory test to measure the amount of carbon dioxide in the liquid part of the blood, called the serum. In the body, most of the CO2 is in the form of a substance called bicarbonate (HCO3-). Therefore, the CO2 blood test is really a measure of the blood bicarbonate level.

    Time frame: Baseline and 10 weeks

  8. Changes in Potassium level

    Potassium test measures the amount of potassium in the fluid portion (serum) of the blood. Potassium (K+) helps nerves and muscles communicate. It also helps move nutrients into cells and waste products out of cells.

    Time frame: Baseline and 10 weeks

  9. Changes in Sodium level

    The sodium blood test measures the concentration of sodium in the blood.

    Time frame: Baseline and 10 weeks

  10. Changes in Chloride

    Chloride is a type of electrolyte. It works with other electrolytes such as potassium, sodium, and carbon dioxide (CO2). These substances help keep the proper balance of body fluids and maintain the body's acid-base balance.

    Time frame: Baseline and 10 weeks

  11. Changes in Calcium

    The calcium blood test measures the level of calcium in the blood. All cells need calcium in order to work. Calcium helps build strong bones and teeth. It is important for heart function, and helps with muscle contraction, nerve signaling, and blood clotting.

    Time frame: Baseline and 10 weeks

  12. Changes in Creatine

    The creatinine blood test measures the level of creatinine in the blood. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply energy mainly to muscles. This test is done to see how well your kidneys work. Creatinine is removed from the body entirely by the kidneys. If kidney function is not normal, the creatinine level in your blood will increase. This is because less creatinine is excreted through your urine.

    Time frame: Baseline and 10 weeks

  13. Changes in Blood Urea Nitrogen (BUN)

    Urea nitrogen is what forms when protein breaks down. The BUN test measures the amount of urea nitrogen in the blood and is often done to check kidney function.

    Time frame: Baseline and 10 weeks

  14. Changes in White Blood Count (WBC)

    WBC count is a blood test to measure the number of white blood cells (WBCs) in the blood. WBCs are also called leukocytes. They help fight infections.

    Time frame: Baseline and 10 weeks

  15. Changes in Red Blood Count (RBC)

    An RBC count is a blood test that measures amount of red blood cells (RBCs). RBCs contain hemoglobin, which carries oxygen. How much oxygen the body tissues get depends on amount of RBCs and how well they work.

    Time frame: Baseline and 10 weeks

  16. Changes in Hemoglobin

    Hemoglobin is a protein in red blood cells that carries oxygen. The hemoglobin test measures how much hemoglobin is in your blood.

    Time frame: Baseline and 10 weeks

  17. Changes in Hematocrit

    Hematocrit is a blood test that measures how much of a person's blood is made up of red blood cells. This measurement depends on the number of and size of the red blood cells.

    Time frame: Baseline and 10 weeks

  18. Changes in Platelet

    A platelet count is a lab test to measure how many platelets is in the blood. Platelets are parts of the blood that help the blood clot. They are smaller than red or white blood cells.

    Time frame: Baseline and 10 weeks

  19. Changes in hemoglobin A1c

    A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling your blood sugar to help prevent complications from diabetes.

    Time frame: Baseline and 10 weeks

  20. Changes in Glucose

    A blood sugar test measures the amount of a sugar called glucose in the blood. Glucose is a major source of energy for most cells of the body, including brain cells. Glucose is a building block for carbohydrates. Carbohydrates are quickly turned into glucose in the body. This can raise the blood glucose level. Hormones made in the body help control blood glucose level.

    Time frame: Baseline and 10 weeks

  21. Changes in Total Cholesterol

    Cholesterol is a fat (also called a lipid) that your body needs to work properly. Too much bad cholesterol can increase your chance of getting heart disease, stroke, and other problems.

    Time frame: Baseline and 10 weeks

  22. Changes in High density lipoprotein (HDL cholesterol)

    HDL is one of the three main types of lipoproteins and part of the lipid panel.

    Time frame: Baseline and 10 weeks

  23. Changes in Low density lipoprotein (LDL cholesterol)

    LDL is one of the three main types of lipoproteins and part of the lipid panel.

    Time frame: Baseline and 10 weeks

  24. Changes in Triglycerides

    The triglyceride level is a blood test to measure the amount of triglycerides in the blood. Triglycerides are a type of fat.

    Time frame: Baseline and 10 weeks

  25. Changes in aspartate aminotransferase (AST)

    The aspartate aminotransferase (AST) blood test measures the level of the enzyme AST in the blood. AST is an enzyme found in high levels in the liver, heart, and muscles. It is also found in lesser amounts in other tissues. An enzyme is a protein that causes a specific chemical change in the body.

    Time frame: Baseline and 10 weeks

  26. Changes in alanine transaminase (ALT)

    The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.

    Time frame: Baseline and 10 weeks

  27. Changes in albumin

    Albumin is a protein made by the liver. A serum albumin test measures the amount of this protein in the clear liquid portion of the blood.

    Time frame: Baseline and 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Anonymized data can be made available upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 49 months is above that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Jan 19, 2022
StartActual
Nov 20, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05197309
Responsible party
Chinara Tate (Clinical Nutrition Coordinator, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 19, 2022
Start date
Nov 20, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Chinara Tate
Contact
chinara.tate@mssm.edu
(212) 659-8724
Tom Hildebrandt
Contact
tom.hildebrandt@mssm.edu
212-659-8673
Chinara Tate
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion